REGENXBIO (RGNX) Stock Price, News & Analysis

$15.90
+0.26 (+1.66%)
(As of 04/23/2024 ET)
Today's Range
$15.52
$16.28
50-Day Range
$15.64
$24.61
52-Week Range
$11.83
$28.80
Volume
360,158 shs
Average Volume
442,574 shs
Market Capitalization
$779.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.45

REGENXBIO MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
141.9% Upside
$38.45 Price Target
Short Interest
Bearish
8.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.66mentions of REGENXBIO in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.22 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.98) to ($3.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.66 out of 5 stars

Medical Sector

69th out of 909 stocks

Biological Products, Except Diagnostic Industry

9th out of 156 stocks

RGNX stock logo

About REGENXBIO Stock (NASDAQ:RGNX)

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

RGNX Stock Price History

RGNX Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
REGENXBIO's (RGNX) Buy Rating Reaffirmed at Stifel Nicolaus
Where Regenxbio Stands With Analysts
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
RBC Capital gets more bullish on Regenxbio, upgrades shares
Latest News for Regenxbio Stock (NASDAQ:RGNX)
Leerink gets more bullish on Regenxbio, upgrades shares
See More Headlines
Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/23/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RGNX
Fax
N/A
Employees
344
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.45
High Stock Price Target
$55.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+141.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-263,490,000.00
Net Margins
-291.99%
Pretax Margin
-292.15%

Debt

Sales & Book Value

Annual Sales
$90.24 million
Book Value
$7.09 per share

Miscellaneous

Free Float
42,604,000
Market Cap
$779.74 million
Optionable
Optionable
Beta
1.29
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Kenneth T. MillsMr. Kenneth T. Mills (Age 49)
    President, CEO & Director
    Comp: $1.02M
  • Mr. Vittal K. Vasista (Age 56)
    Executive VP & CFO
    Comp: $671.41k
  • Mr. Curran M. Simpson M.S. (Age 62)
    Executive VP & COO
    Comp: $677.7k
  • Dr. Olivier Danos Ph.D. (Age 66)
    Executive VP & Chief Scientific Officer
    Comp: $728.06k
  • Dr. Stephen Pakola M.D. (Age 55)
    Executive VP & Chief Medical Officer
    Comp: $673.76k
  • Mr. Patrick J. Christmas II (Age 53)
    J.D., Executive VP & Chief Legal Officer
    Comp: $1.11M
  • Ms. Shiva G. Fritsch
    Chief Communications & People Officer
  • Dr. Laura A. Coruzzi J.D. (Age 70)
    Ph.D., Executive Vice President of Intellectual Property
  • Dr. Ram Palanki Pharm.D. (Age 47)
    Executive VP of Commercial Strategy & Operations

RGNX Stock Analysis - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGNX shares.
View RGNX analyst ratings
or view top-rated stocks.

What is REGENXBIO's stock price target for 2024?

12 equities research analysts have issued 12 month price objectives for REGENXBIO's stock. Their RGNX share price targets range from $21.00 to $55.00. On average, they predict the company's share price to reach $38.45 in the next year. This suggests a possible upside of 141.9% from the stock's current price.
View analysts price targets for RGNX
or view top-rated stocks among Wall Street analysts.

How have RGNX shares performed in 2024?

REGENXBIO's stock was trading at $17.95 at the start of the year. Since then, RGNX shares have decreased by 11.4% and is now trading at $15.90.
View the best growth stocks for 2024 here
.

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our RGNX earnings forecast
.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its quarterly earnings results on Tuesday, February, 27th. The biotechnology company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by $0.16. The biotechnology company earned $22.30 million during the quarter, compared to analyst estimates of $34.01 million. REGENXBIO had a negative net margin of 291.99% and a negative trailing twelve-month return on equity of 68.18%. REGENXBIO's revenue for the quarter was down 28.8% compared to the same quarter last year. During the same quarter last year, the company earned ($1.38) EPS.

What ETFs hold REGENXBIO's stock?

ETFs with the largest weight of REGENXBIO (NASDAQ:RGNX) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) and WisdomTree BioRevolution Fund (WDNA).Harbor Disruptive Innovation ETF (INNO).

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.22%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Allan M Fox, Kenneth T Mills, Kenneth T Mills, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends
.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RGNX) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners